MEDP Medpace Holdings, Inc.
MEDP Medpace Holdings, Inc.
Healthcare · Diagnostics & Research
Desk view
Market read
Scan convergence 1 scan as of 2026-10-23 1 neutral converging
POC $600.15 · VWAP $527.76 · +26.8% vs 12m avg buyer
Insiders selling 0 buy / 6 sell · Form 4, 90d $157.8M sold last open-market sell Troendle August J.
Cluster CEO, CFO + 3 others sold $51.5M, Aug 21–31
Coverage
1 related campaign
MEDP Price Structure
Loading timeframes…
Peers
Every watchlist MEDP belongs to, members best 30-day change first — MEDP highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-capital-cycle
@ibb
Reported EPS $4.84 versus analyst consensus of $4.46 (+8.5%).
full note →Against street estimates
How MEDP's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
Recent news
Headlines about MEDP from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled today · Oct 23
- Medpace Holdings (MEDP) Latest News & Stock Updates - Page 1
- MEDP News Today | Why did Medpace stock go up today? $MEDP
- Medpace Holdings Inc (MEDP) Stock Price & News - Google Finance
- Medpace (MEDP) Q3 2026 Earnings Call Transcript | The Motley Fool
- Medpace Holdings, Inc. Reports Third Quarter 2026 Results | Medpace Holdings, Inc.
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
MEDP research tape
61 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Desk commentary
Authored analysis and challenge notes tied to MEDP.
Vertical: Biotech Capital Cycle — the theme is confirmed; the question is now entries